ArticleAnnals of translational medicine2023

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression.

Julia Foldi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.